MET across 5 cancers
MET is on the target list of 5 of the briefings. A drug aimed at it carries an FDA label naming the disease in 3, and is approved for some indication in 5. In the reference cohorts of the 5 with a mutation landscape it is altered in at least 5% of patients in 0 and in under 2% in 2 (Kidney cancer, Uveal melanoma) — a target there by expression, dependency or drug label, not by mutation.
| Disease | Label status | Furthest stage (Open Targets) | Distinct drugs | Cell-therapy trials | Altered in the reference cohort |
|---|---|---|---|---|---|
| Lung cancer | approved here Capmatinib, Tepotinib | approved | 35 | 0 via c-MET | 3.71% mut · 2.15% amp · 0.59% del n=566 |
| Hepatocellular carcinoma | approved here Cabozantinib | approved | 35 | — | 0.55% mut · 2.45% amp n=366 |
| Kidney cancer | approved here Cabozantinib | approved | 35 | — | 0.75% mut · 0.59% amp n=402 |
| Gastric cancer | approved elsewhere | approved | 35 | — | 1.61% mut · 2.74% amp · 0.23% del n=436 |
| Uveal melanoma | approved elsewhere | approved | 35 | 0 via cMET | 0.0% mut n=80 |
"Approved here" means a drug Open Targets records as aimed at MET carries an FDA label that names that disease, per the briefing's openFDA stage. "Approved elsewhere" means the drug is approved for some other indication. Stage is the furthest Open Targets clinical stage among drugs aimed at the gene, in any indication; the database is reported as it is, and it lags some approvals. Cell-therapy trials are counted on the antigen the briefing maps the gene to, from ClinicalTrials.gov. The last column is the disease's mutation landscape: non-silent mutation, high-level amplification and deep deletion as percentages of the reference cohort's patients, each over its own denominator; "not on panel" means the reference cohort could not have called the gene.